Nicholas Endres

Biochemistry, Genetics and Molecular Biology · Life Sciences

14h-index2.8kcitations53works0.72yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

PI3K/AKT/mTOR signaling in cancer(16), Chronic Lymphocytic Leukemia Research(9), Advanced Breast Cancer Therapies(9), HER2/EGFR in Cancer Research(7), Monoclonal and Polyclonal Antibodies Research(7)

Publications53 total

Figure S4 from RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy
2025Open Access
Figure S2 from RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy
2025Open Access
Figure S6 from RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy
2025Open Access
Figure S5 from RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy
2025Open Access
Figure S3 from RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy
2025Open Access
Figure S1 from RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy
2025Open Access
Rational design of potent small-molecule SMARCA2/A4 degraders acting via the recruitment of FBXO22
Nature Communications·2025· 4 citedOpen Access
Correction to “Combining Fundamental Kinetics and Standard Alkylation Assays to Prioritize Lead-like KRAS G12C Inhibitors”
ACS Omega·2025Open Access
Rational design of potent small molecule SMARCA2/A4(BRM/BRG1) degraders acting via the recruitment of FBXO22
2025· 1 citedOpen Access
Rational design of potent small molecule SMARCA2/A4 (BRM/BRG1) degraders acting via the recruitment of FBXO22
2025· 2 citedOpen Access
Combining Fundamental Kinetics and Standard Alkylation Assays to Prioritize Lead-Like KRAS G12C Inhibitors
ACS Omega·2024· 1 citedOpen Access
A translational QSP model to characterize the preclinical pharmacodynamics of combining a KRAS G12C inhibitor with a SHP2 inhibitor
2024Open Access
Structure-Based Design and Evaluation of Reversible KRAS G13D Inhibitors
ACS Medicinal Chemistry Letters·2023· 6 citedOpen Access
Data from RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy
2023Open Access
Figure S5 from RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy
2023Open Access
Figure S1 from RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy
2023Open Access
Figure S4 from RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy
2023Open Access
Figure S3 from RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy
2023Open Access
Figure S4 from RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy
2023Open Access
Figure S1 from RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Emile G. Plise(24), Laurent Salphati(23), Emily J. Hanan(22), Kyle A. Edgar(22), Lori S. Friedman(22), Steven T. Staben(22), Timothy P. Heffron(22), Michelle Nannini(21), Deepak Sampath(21), Kyung Song(21), Marc Hafner(21), Mark Merchant(21), Jason Oeh(20), Rebecca Hong(20), Lilian Phu(20), William F. Forrest(20), Eric Stawiski(20), Jane Guan(20), Jeffrey J. Wallin(20), Jonathan Cheong(20)